A recent meta-analysis of six randomized controlled trials, including a total of 8788 patients with HFmrEF or HFpEF, demonstrated that treatment with GLP-1 RAs led to a significant reduction in the composite outcome of CV death or worsening HF events [177]. Here, GLP1R is linked to hydrops fetalis.